Choices in Medical Management for Prevention of Acute Ischemic Stroke

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2002 Mar 20

PMID 11898498

Authors

J D Fleck

J Biller

Affiliations

Soon will be listed here.

Abstract

Stroke is a leading cause of death and disability. Although advances are being made in the treatment of acute ischemic stroke, its prevention is equally as important. Identification and management of risk factors are essential. Medical therapy is also helpful in the secondary prevention of ischemic stroke. There are currently four platelet-antiaggregating agents used to prevent ischemic stroke: aspirin, aspirin plus dipyridamole, clopidogrel, and ticlopidine. The relevant studies proving their efficacy are noted, as are some of their similarities and differences. The use of warfarin is also discussed.

References

Albers G, Easton J, Sacco R, Teal P . Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998; 114(5 Suppl):683S-698S. DOI: 10.1378/chest.114.5_supplement.683s. View

. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348(9038):1329-39. DOI: 10.1016/s0140-6736(96)09457-3. View

Hobson 2nd R, Krupski W, Weiss D . Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. J Vasc Surg. 1993; 17(2):257-63; discussion 263-5. View

. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269(23):3015-23. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Stein J, McBride P . Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. Arch Intern Med. 1998; 158(12):1301-6. DOI: 10.1001/archinte.158.12.1301. View

. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24):3255-64. View

Eikelboom J, Hankey G, Anand S, Lofthouse E, Staples N, Baker R . Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke. 2000; 31(5):1069-75. DOI: 10.1161/01.str.31.5.1069. View

Fuster V, DYKEN M, Vokonas P, Hennekens C . Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation. 1993; 87(2):659-75. DOI: 10.1161/01.cir.87.2.659. View

10.

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

11.

Mohr J, Caplan L, Melski J, GOLDSTEIN R, Duncan G, Kistler J . The Harvard Cooperative Stroke Registry: a prospective registry. Neurology. 1978; 28(8):754-62. DOI: 10.1212/wnl.28.8.754. View

12.

Bennett C, Connors J, Carwile J, Moake J, Bell W, Tarantolo S . Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000; 342(24):1773-7. DOI: 10.1056/NEJM200006153422402. View

13.

DYKEN M, Barnett H, Easton J, Fields W, Fuster V, Hachinski V . Low-dose aspirin and stroke. "It ain't necessarily so". Stroke. 1992; 23(10):1395-9. DOI: 10.1161/01.str.23.10.1395. View

14.

Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C . Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999; 282(21):2003-11. DOI: 10.1001/jama.282.21.2003. View

15.

Gorelick P, Sacco R, Smith D, Alberts M, Rader D, Ross J . Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999; 281(12):1112-20. DOI: 10.1001/jama.281.12.1112. View

16.

Gent M, Blakely J, Easton J, Ellis D, Hachinski V, Harbison J . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 1(8649):1215-20. DOI: 10.1016/s0140-6736(89)92327-1. View

17.

Bots M, Launer L, Lindemans J, Hoes A, Hofman A, Witteman J . Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999; 159(1):38-44. DOI: 10.1001/archinte.159.1.38. View

18.

. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308(6921):81-106. PMC: 2539220. View

19.

Connolly S, Laupacis A, Gent M, Roberts R, Cairns J, Joyner C . Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991; 18(2):349-55. DOI: 10.1016/0735-1097(91)90585-w. View

20.

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View